Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Novel PCSK9 Inhibitors and Other Novel Antidyslipidemic ( For reducing cardiovascular risk) | Physician & Payer Forum | US | 2015
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
Gram-Negative Infections due to Carbapenem-Resistant Organisms | Decision Base | US | 2015
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics…
What Are the U.S. Market Access and Prescribing Hurdles for the Oral Therapies Looming Large on the Horizon for Atherothrombotic Diseases? | Physician & Payer Forum | US | 2015
A Survey of Non-interventional Cardiologists and Managed Care Organization Pharmacy and Medical Directors Atherosclerosis refers to the thickening of arterial walls due to deposition of plaque;…
Squamous Cell Carcinoma of the Head and Neck | Niche and Rare Pharmacor | G7 | 2014
Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…
Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 1 | 2014
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…
Hepatitis C Virus: How Will More Efficacious Direct-Acting Antivirals Influence US Prescribing and Reimbursement for This Dynamic Indication? | Physician & Payer Forum | US | 2014
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
Shifts in the U.S. Rheumatoid Arthritis Market Access Landscape Due to Oral Kinase Inhibitors, New Biologics, and Biosimilars: Insights from Payers and Physicians | Physician & Payer Forum | US | 2014
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
